CN1686370A - 一种治疗儿童抽动症的药物及其制备方法 - Google Patents
一种治疗儿童抽动症的药物及其制备方法 Download PDFInfo
- Publication number
- CN1686370A CN1686370A CNA2005100596612A CN200510059661A CN1686370A CN 1686370 A CN1686370 A CN 1686370A CN A2005100596612 A CNA2005100596612 A CN A2005100596612A CN 200510059661 A CN200510059661 A CN 200510059661A CN 1686370 A CN1686370 A CN 1686370A
- Authority
- CN
- China
- Prior art keywords
- medicine
- syndrome
- amount
- tourette
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title description 24
- 208000011580 syndromic disease Diseases 0.000 title description 7
- 208000005392 Spasm Diseases 0.000 title description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 241000255791 Bombyx Species 0.000 claims description 9
- 241000644519 Chloritis Species 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000011021 lapis lazuli Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 241000345998 Calamus manan Species 0.000 claims description 2
- 229940126678 chinese medicines Drugs 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000003595 mist Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 235000012950 rattan cane Nutrition 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 241000600857 Astrodia Species 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 208000016620 Tourette disease Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 229960003638 dopamine Drugs 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 4
- 229960004046 apomorphine Drugs 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000001577 neostriatum Anatomy 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- SBAJRGRUGUQKAF-UHFFFAOYSA-N 3-(2-cyanoethylamino)propanenitrile Chemical compound N#CCCNCCC#N SBAJRGRUGUQKAF-UHFFFAOYSA-N 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000009194 climbing Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010010964 Coprolalia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010057315 Daydreaming Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- 206010003830 Automatism Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
药名 | 实例1 | 实例2 | 实例3 |
熟地黄天麻龙胆草龟板钩藤生龙骨僵蚕青礞石法半夏 | 8405044204204201260420840504 | 7504043753753751100375750404 | 340304220220220800220640304 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100596612A CN1318074C (zh) | 2005-03-30 | 2005-03-30 | 一种治疗儿童抽动症的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100596612A CN1318074C (zh) | 2005-03-30 | 2005-03-30 | 一种治疗儿童抽动症的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1686370A true CN1686370A (zh) | 2005-10-26 |
CN1318074C CN1318074C (zh) | 2007-05-30 |
Family
ID=35304412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100596612A Active CN1318074C (zh) | 2005-03-30 | 2005-03-30 | 一种治疗儿童抽动症的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1318074C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103751722A (zh) * | 2014-01-22 | 2014-04-30 | 南京海思创新生物科技有限公司 | 治疗小儿抽动症的中药口服液的制备方法 |
CN106474347A (zh) * | 2016-12-06 | 2017-03-08 | 郑卫强 | 一种治疗小儿抽动症的中成药 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1175838C (zh) * | 2001-02-23 | 2004-11-17 | 北京康兴达医疗技术开发有限公司 | 一种健脑止抽药物及其制备方法 |
-
2005
- 2005-03-30 CN CNB2005100596612A patent/CN1318074C/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103751722A (zh) * | 2014-01-22 | 2014-04-30 | 南京海思创新生物科技有限公司 | 治疗小儿抽动症的中药口服液的制备方法 |
CN103751722B (zh) * | 2014-01-22 | 2016-01-27 | 南京海思创新生物科技有限公司 | 治疗小儿抽动症的中药口服液的制备方法 |
CN106474347A (zh) * | 2016-12-06 | 2017-03-08 | 郑卫强 | 一种治疗小儿抽动症的中成药 |
Also Published As
Publication number | Publication date |
---|---|
CN1318074C (zh) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100534474C (zh) | 一种具有增强免疫功效的组合物及其制备方法和其用途 | |
CN107233412A (zh) | 一种促进睡眠的复方精油组合物及其制备方法和用途 | |
CN101716240A (zh) | 一种用于改善睡眠、补气生血的制剂 | |
CN102178853B (zh) | 一种治疗小儿癫痫的中药制剂及其制备方法 | |
CN102894152A (zh) | 一种保健茶及其制备方法 | |
CN1318074C (zh) | 一种治疗儿童抽动症的药物及其制备方法 | |
CN107126510A (zh) | 一种治疗儿童抽动障碍综合征的中药组合物及其应用 | |
CN1257743C (zh) | 一种天麻复方药物及其制备方法和应用 | |
CN1814214A (zh) | 一种治疗体形消瘦、体质虚弱的中药组合物及其制备方法 | |
CN103520646B (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
CN102188471A (zh) | 一种治疗老年性痴呆症的药物组合物及其制备方法 | |
CN104922371B (zh) | 组合物在制备治疗短暂性和慢性抽动障碍药物中的用途 | |
CN114010736A (zh) | 调摄焦虑抑郁失眠症的中药组合物及其制备方法 | |
CN1277567C (zh) | 治疗精神神经系统疾病的药物组合物及它的制备方法 | |
CN102631503A (zh) | 一种抗疲劳中药组合物及其制备方法 | |
CN1380071A (zh) | 用于治疗精神病和痫病的中药 | |
CN102872253A (zh) | 一种用于血虚体质的组合物及其制备方法和用途 | |
CN110179889B (zh) | 一种用于戒断海洛因毒瘾的中药组合物及其制备方法 | |
CN1175838C (zh) | 一种健脑止抽药物及其制备方法 | |
CN114982972B (zh) | 一种选用血肉动物提取优质蛋白与中草药制备气阴虚康养胶囊食品的方法 | |
CN108186821A (zh) | 一种治疗神经性头痛的中药组合物及其制备方法和用途 | |
CN1453029A (zh) | 一种治疗老年性痴呆的中药组合物 | |
CN103006988B (zh) | 一种治疗多发性抽动症的中药组合物 | |
CN108704080B (zh) | 一种治疗肾阴虚型抑郁症的药物及其制备方法 | |
CN1298374C (zh) | 一种用于戒毒的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING GOLDBAY CHILDREN S HOSPITAL Free format text: FORMER OWNER: ZHUO JINHUA Effective date: 20131210 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100089 HAIDIAN, BEIJING TO: 100142 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131210 Address after: North Building 8 Building No. 100142 Beijing City, Haidian District Fuwai liangjiadian 1, 2, 3 Patentee after: Beijing Hospital of traditional Chinese medicine. Address before: 100089 Beijing City, Haidian District Zizhuyuan Road A gladful International Center No. 116 room 510 Patentee before: Zhuo Jinhua |
|
ASS | Succession or assignment of patent right |
Owner name: KANGYUAN PHARMCEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING GOLDBAY CHILDREN S HOSPITAL Effective date: 20140116 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Xiao Wei Inventor after: Zhuo Jinhua Inventor before: Zhuo Jinhua |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100142 HAIDIAN, BEIJING TO: 222001 LIANYUNGANG, JIANGSU PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHUO JINHUA TO: XIAO WEI ZHUO JINHUA |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140116 Address after: 222001 Jiangsu Province, Lianyungang city Sinpo District Road No. 58 Chang Kang Pharmaceutical Research Institute of strategic research department Patentee after: Kangyuan Pharmceutical Co., Ltd. Address before: North Building 8 Building No. 100142 Beijing City, Haidian District Fuwai liangjiadian 1, 2, 3 Patentee before: Beijing Hospital of traditional Chinese medicine. |